These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 25081901)
1. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901 [TBL] [Abstract][Full Text] [Related]
2. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059 [TBL] [Abstract][Full Text] [Related]
3. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117 [TBL] [Abstract][Full Text] [Related]
4. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Bowles DW; Senzer N; Hausman D; Peterson S; Vo A; Walker L; Cohen RB; Jimeno A Invest New Drugs; 2014 Dec; 32(6):1197-203. PubMed ID: 24916771 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588 [No Abstract] [Full Text] [Related]
6. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512 [TBL] [Abstract][Full Text] [Related]
7. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089 [TBL] [Abstract][Full Text] [Related]
8. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status. Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576 [TBL] [Abstract][Full Text] [Related]
9. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140 [TBL] [Abstract][Full Text] [Related]
10. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481 [TBL] [Abstract][Full Text] [Related]
11. Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers. Bastit V; Bon-Mardion N; Picquenot JM; Rainville V; Moldovan C; François A; Loeb A; Thureau S; Manu D; Jardin F; Marie JP; Di Fiore F; Clatot F Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):541-550. PubMed ID: 30523411 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA; Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666 [TBL] [Abstract][Full Text] [Related]
13. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015 [TBL] [Abstract][Full Text] [Related]
15. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083 [TBL] [Abstract][Full Text] [Related]
16. Is biomarker research advancing in the era of personalized medicine for head and neck cancer? Yokota T Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754 [TBL] [Abstract][Full Text] [Related]
17. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab. Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873 [TBL] [Abstract][Full Text] [Related]
18. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260 [TBL] [Abstract][Full Text] [Related]
19. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance. Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725 [TBL] [Abstract][Full Text] [Related]
20. An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents. Péron J; Polivka V; Chabaud S; Poupart M; Ceruse P; Ramade A; Girodet D; Zrounba P; Fayette J BMC Cancer; 2014 Jul; 14():504. PubMed ID: 25011678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]